Photo: aprott/Getty Images
In December, Novo Nordisk announced that the Food and Drug Administration had approved its once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. It remains the only GLP-1 pill on the market, though Eli Lilly will potentially get FDA approval in the second quarter and other drugmakers are not far behind.
Ferrin Williams, PharmD MBA, chief pharmacy officer at Scripta Insights, was asked what happens now, the benefits of a pill over an injectable and how these medications affect care plans for patients.
Q. Now that the Wegovy pill is here, people want to know, how do I get this – with or without insurance coverage – and what will it cost me? Can you please shed some light on this?
A. The key thing for patients to understand is that “oral” does not automatically mean easier or cheaper. The pill is still prescription-only, and insurance coverage for weight-loss drugs remains inconsistent.
We’re hearing that 85% of all Wegovy pill prescriptions right now being processed with insurance are not being covered yet. Many plans are slow to add new formulations to the formulary, so early access is often limited or requires prior authorization.
Out-of-pocket costs vary widely. Without insurance, manufacturer programs price lower doses near $149–$199 monthly and higher doses around $299.
For patients without coverage, the price they hear at the pharmacy counter can vary dramatically depending on whether a manufacturer program is applied correctly. For example, one patient was quoted the pharmacy’s cash price, based on Average Wholesale Acquisition cost of ~$1,600. What we consistently see is confusion – patients don’t know which pharmacy to use, which pricing programs apply, or how much they’ll actually owe until they’re already at the counter. Helping patients understand their true out-of-pocket cost before filling is where navigation really matters.
Q. Novo Nordisk is the first to enter the pill market for a GLP-1 drug. Do you think other pharma companies such as Eli Lilly are far behind? Will competition lower the price of these popular drugs, and what’s the best way for patients to find the lowest price?
A. Other manufacturers are not far behind – oral GLP-1s are clearly where the market is heading. That said, competition in this category doesn’t usually show up as a rapid drop in list price. Instead, it tends to show up through rebates, patient assistance programs and channel-specific pricing that can be difficult for patients to navigate.
From a patient perspective, the “lowest price” isn’t a single number. It depends on insurance status, pharmacy, strength of the pill and whether manufacturer pricing or discounts are being applied correctly. The most effective way to find the lowest cost is to compare real out-of-pocket options across pharmacies and fulfillment channels, rather than assuming the first quoted price is the best one.
Q. Does patient access to GLP-1 pills help hospitals achieve long-term success for patients who have chronic conditions?
A. Potentially, but access alone isn’t enough. Hospitals benefit when patients can consistently start, stay on and adhere to therapy – not simply when a new formulation exists. Oral options may reduce barriers for patients who are unwilling or unable to use injectables, but daily dosing introduces its own adherence challenges.
Long-term success comes from pairing access with affordability, education and care coordination. Without those pieces, the clinical benefit is harder to sustain.
Q. What is the outlook of people keeping the weight off after ending GLP-1 treatment?
A. For most patients, weight regain after stopping GLP-1 therapy is common.
These medications manage appetite and metabolism while they’re being taken, but they don’t permanently change the body’s underlying metabolic set point.
That doesn’t diminish their value – it just means they should be framed realistically. In many cases, GLP-1s function more like chronic therapy than a short-term intervention. The best outcomes happen when patients and providers plan for long-term use or have a clear strategy in place for what comes next after treatment ends.
Email the writer: SMorse@himss.org